HIF-1α-independent hypoxia-induced rapid PTK6 stabilization is associated with increased motility and invasion

References

• Derry JJ, Prins GS, Ray V, Tyner AL. Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene 2003; 22:4212 - 20; http://dx.doi.org/10.1038/sj.onc.1206465; PMID: 12833144
   PubMed Web of Science ®Google Scholar
• Kasprzycka M, Majewski M, Wang ZJ, Ptasznik A, Wysocka M, Zhang Q, Marzec M, Gimotty P, Crompton MR, Wasik MA. Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in lymphocytes. Am J Pathol 2006; 168:1631 - 41; http://dx.doi.org/10.2353/ajpath.2006.050521; PMID: 16651629
   PubMed Web of Science ®Google Scholar
• Lin HS, Berry GJ, Fee WE Jr., Terris DJ, Sun Z. Identification of tyrosine kinases overexpressed in head and neck cancer. Arch Otolaryngol Head Neck Surg 2004; 130:311 - 6; http://dx.doi.org/10.1001/archotol.130.3.311; PMID: 15023838
   PubMed Web of Science ®Google Scholar
• Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK, Gershenson DM. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther 2006; 5:1136 - 41; http://dx.doi.org/10.4161/cbt.5.9.2953; PMID: 16855388
   PubMed Web of Science ®Google Scholar
• Harvey AJ, Crompton MR. The Brk protein tyrosine kinase as a therapeutic target in cancer: opportunities and challenges. Anticancer Drugs 2004; 15:107 - 11; http://dx.doi.org/10.1097/00001813-200402000-00002; PMID: 15075665
   PubMed Web of Science ®Google Scholar
• Zhao C, Chen Y, Zhang W, Zhang J, Xu Y, Li W, Chen S, Deng A. Expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer and their clinical and prognostic significance. Onco Targets Ther 2013; 6:183 - 8; PMID: 23525678
   PubMed Web of Science ®Google Scholar
• Aubele M, Auer G, Walch AK, Munro A, Atkinson MJ, Braselmann H, Fornander T, Bartlett JM. PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer 2007; 96:801 - 7; http://dx.doi.org/10.1038/sj.bjc.6603613; PMID: 17299391
   PubMed Web of Science ®Google Scholar
• Harvey AJ, Pennington CJ, Porter S, Burmi RS, Edwards DR, Court W, Eccles SA, Crompton MR. Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage. Am J Pathol 2009; 175:1226 - 34; http://dx.doi.org/10.2353/ajpath.2009.080811; PMID: 19661439
   PubMed Web of Science ®Google Scholar
• Ostrander JH, Daniel AR, Lofgren K, Kleer CG, Lange CA. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res 2007; 67:4199 - 209; http://dx.doi.org/10.1158/0008-5472.CAN-06-3409; PMID: 17483331
   PubMed Web of Science ®Google Scholar
• Brauer PM, Zheng Y, Wang L, Tyner AL. Cytoplasmic retention of protein tyrosine kinase 6 promotes growth of prostate tumor cells. Cell Cycle 2010; 9:4190 - 9; http://dx.doi.org/10.4161/cc.9.20.13518; PMID: 20953141
   PubMed Web of Science ®Google Scholar
• Castro NE, Lange CA. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells. Breast Cancer Res 2010; 12:R60; http://dx.doi.org/10.1186/bcr2622; PMID: 20687930
   PubMed Web of Science ®Google Scholar
• Kamalati T, Jolin HE, Mitchell PJ, Barker KT, Jackson LE, Dean CJ, Page MJ, Gusterson BA, Crompton MR. Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem 1996; 271:30956 - 63; http://dx.doi.org/10.1074/jbc.271.48.30956; PMID: 8940083
   PubMed Web of Science ®Google Scholar
• Qiu H, Zappacosta F, Su W, Annan RS, Miller WT. Interaction between Brk kinase and insulin receptor substrate-4. Oncogene 2005; 24:5656 - 64; http://dx.doi.org/10.1038/sj.onc.1208721; PMID: 15870689
   PubMed Web of Science ®Google Scholar
• Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 2008; 68:152 - 61; http://dx.doi.org/10.1158/0008-5472.CAN-07-2126; PMID: 18172307
   PubMed Web of Science ®Google Scholar
• Haegebarth A, Perekatt AO, Bie W, Gierut JJ, Tyner AL. Induction of protein tyrosine kinase 6 in mouse intestinal crypt epithelial cells promotes DNA damage-induced apoptosis. Gastroenterology 2009; 137:945 - 54; http://dx.doi.org/10.1053/j.gastro.2009.05.054; PMID: 19501589
   PubMed Web of Science ®Google Scholar
• Zheng Y, Gierut J, Wang Z, Miao J, Asara JM, Tyner AL. Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT. Oncogene 2013; 32:4304 - 12; PMID: 23027128
   PubMed Web of Science ®Google Scholar
• Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le QT, Giaccia AJ. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009; 15:35 - 44; http://dx.doi.org/10.1016/j.ccr.2008.11.012; PMID: 19111879
   PubMed Web of Science ®Google Scholar
• Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58:1408 - 16; PMID: 9537241
   PubMed Web of Science ®Google Scholar
• Vaupel P, Höckel M. Tumor oxygenation and its relevance to tumor physiology and treatment. Adv Exp Med Biol 2003; 510:45 - 9; http://dx.doi.org/10.1007/978-1-4615-0205-0_8; PMID: 12580403
   PubMed Web of Science ®Google Scholar
• Vaupel P, Mayer A, Höckel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004; 381:335 - 54; http://dx.doi.org/10.1016/S0076-6879(04)81023-1; PMID: 15063685
   PubMed Web of Science ®Google Scholar
• Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012; 148:399 - 408; http://dx.doi.org/10.1016/j.cell.2012.01.021; PMID: 22304911
   PubMed Web of Science ®Google Scholar
• Regan Anderson TM, Peacock DL, Daniel AR, Hubbard GK, Lofgren KA, Girard BJ, Schörg A, Hoogewijs D, Wenger RH, Seagroves TN, et al. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression. Cancer Res 2013; 73:5810 - 20; http://dx.doi.org/10.1158/0008-5472.CAN-13-0523; PMID: 23928995
   PubMed Web of Science ®Google Scholar
• Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, Ratcliffe PJ. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 2009; 284:16767 - 75; http://dx.doi.org/10.1074/jbc.M901790200; PMID: 19386601
   PubMed Web of Science ®Google Scholar
• Schödel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 2011; 117:e207 - 17; http://dx.doi.org/10.1182/blood-2010-10-314427; PMID: 21447827
   PubMed Web of Science ®Google Scholar
• Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010; 16:5928 - 35; http://dx.doi.org/10.1158/1078-0432.CCR-10-1360; PMID: 20962028
   PubMed Web of Science ®Google Scholar
• Ostrander JH, Daniel AR, Lange CA. Brk/PTK6 signaling in normal and cancer cell models. Curr Opin Pharmacol 2010; 10:662 - 9; http://dx.doi.org/10.1016/j.coph.2010.08.007; PMID: 20832360
   PubMed Web of Science ®Google Scholar
• Brauer PM, Tyner AL. Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK. Biochim Biophys Acta 2010; 1806:66 - 73; PMID: 20193745
   PubMed Web of Science ®Google Scholar
• Scrace S, O’Neill E, Hammond EM, Pires IM. Use of the xCELLigence system for real-time analysis of changes in cellular motility and adhesion in physiological conditions. Methods Mol Biol 2013; 1046:295 - 306; http://dx.doi.org/10.1007/978-1-62703-538-5_17; PMID: 23868595
   PubMedGoogle Scholar
• Singh AJ, Meyer RD, Navruzbekov G, Shelke R, Duan L, Band H, Leeman SE, Rahimi N. A critical role for the E3-ligase activity of c-Cbl in VEGFR-2-mediated PLCgamma1 activation and angiogenesis. Proc Natl Acad Sci U S A 2007; 104:5413 - 8; http://dx.doi.org/10.1073/pnas.0700809104; PMID: 17372230
   PubMed Web of Science ®Google Scholar
• Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010; 123:725 - 31; http://dx.doi.org/10.1007/s10549-009-0674-9; PMID: 20020197
   PubMed Web of Science ®Google Scholar
• Thien CB, Langdon WY. Negative regulation of PTK signalling by Cbl proteins. Growth Factors 2005; 23:161 - 7; http://dx.doi.org/10.1080/08977190500153763; PMID: 16019438
   PubMed Web of Science ®Google Scholar
• Zhou L, Yang H. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR. PLoS One 2011; 6:e23936; http://dx.doi.org/10.1371/journal.pone.0023936; PMID: 21949687
   PubMedGoogle Scholar
• Kang SA, Lee ST. PTK6 promotes degradation of c-Cbl through PTK6-mediated phosphorylation. Biochem Biophys Res Commun 2013; 431:734 - 9; http://dx.doi.org/10.1016/j.bbrc.2013.01.046; PMID: 23352614
   PubMed Web of Science ®Google Scholar
• Gao Y, Cimica V, Reich NC. Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3. J Biol Chem 2012; 287:20904 - 12; http://dx.doi.org/10.1074/jbc.M111.334144; PMID: 22547065
   PubMed Web of Science ®Google Scholar
• Kang SA, Cho HS, Yoon JB, Chung IK, Lee ST. Hsp90 rescues PTK6 from proteasomal degradation in breast cancer cells. Biochem J 2012; 447:313 - 20; http://dx.doi.org/10.1042/BJ20120803; PMID: 22849407
   PubMed Web of Science ®Google Scholar
• Palka-Hamblin HL, Gierut JJ, Bie W, Brauer PM, Zheng Y, Asara JM, Tyner AL. Identification of beta-catenin as a target of the intracellular tyrosine kinase PTK6. J Cell Sci 2010; 123:236 - 45; http://dx.doi.org/10.1242/jcs.053264; PMID: 20026641
   PubMed Web of Science ®Google Scholar
• Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N, Wang Z, Zou L, Yao J, Lu Y, Epstein CB, et al. PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One 2010; 5:e11729; http://dx.doi.org/10.1371/journal.pone.0011729; PMID: 20668531
   PubMed Web of Science ®Google Scholar
• Aubele M, Spears M, Ludyga N, Braselmann H, Feuchtinger A, Taylor KJ, Lindner K, Auer G, Stering K, Höfler H, et al. In situ quantification of HER2-protein tyrosine kinase 6 (PTK6) protein-protein complexes in paraffin sections from breast cancer tissues. Br J Cancer 2010; 103:663 - 7; http://dx.doi.org/10.1038/sj.bjc.6605836; PMID: 20700126
   PubMed Web of Science ®Google Scholar
• Pires IM, Bencokova Z, Milani M, Folkes LK, Li JL, Stratford MR, Harris AL, Hammond EM. Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res 2010; 70:925 - 35; http://dx.doi.org/10.1158/0008-5472.CAN-09-2715; PMID: 20103649
   PubMed Web of Science ®Google Scholar
• Hammond EM, Mandell DJ, Salim A, Krieg AJ, Johnson TM, Shirazi HA, Attardi LD, Giaccia AJ. Genome-wide analysis of p53 under hypoxic conditions. Mol Cell Biol 2006; 26:3492 - 504; http://dx.doi.org/10.1128/MCB.26.9.3492-3504.2006; PMID: 16611991
   PubMed Web of Science ®Google Scholar
• Haglund K, Schmidt MH, Wong ES, Guy GR, Dikic I. Sprouty2 acts at the Cbl/CIN85 interface to inhibit epidermal growth factor receptor downregulation. EMBO Rep 2005; 6:635 - 41; http://dx.doi.org/10.1038/sj.embor.7400453; PMID: 15962011
   PubMed Web of Science ®Google Scholar
• Pires IM, Olcina MM, Anbalagan S, Pollard JR, Reaper PM, Charlton PA, McKenna WG, Hammond EM. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. Br J Cancer 2012; 107:291 - 9; http://dx.doi.org/10.1038/bjc.2012.265; PMID: 22713662
   PubMed Web of Science ®Google Scholar
• Coutts AS, Pires IM, Weston L, Buffa FM, Milani M, Li JL, Harris AL, Hammond EM, La Thangue NB. Hypoxia-driven cell motility reflects the interplay between JMY and HIF-1α. Oncogene 2011; 30:4835 - 42; http://dx.doi.org/10.1038/onc.2011.188; PMID: 21625218
   PubMed Web of Science ®Google Scholar